Biogen expects full-year 2025 total revenue to decline by a mid-single digit percentage. The company’s stock was down about 6% at 10 a.m. on Wednesday with shares priced at around $131 apiece.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback